Clinical trials: Adenovirus Infections
Malaria
Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso
The purpose of this study is to evaluate the safety of a malaria vaccine, Ad35.CS.01, and how the body reacts to vaccination. Participants will include 48 Berkinabè healthy males and females ages 18-45 years in Burkina Faso.
- Trial name
- NCT01018459
- Testing
- Ad35.CS.01 Circumsporozoite Malaria Vaccine
- Where
- Burkina Faso
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Cancer
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004225
- Testing
- Ad5CMV-p53 gene, radiation therapy
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Breast Cancer, Recurrent Breast Cancer
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)
To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.
- Trial name
- NCT00307229
- Testing
- adenoviral vector encoding rat Her-2/neu
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
HIV Infections
Phase I Study of Vaccination Schedule of Experimental HIV Vaccines
This study will test whether a vaccination schedule of experimental HIV vaccines is safe and whether it causes side effects in healthy adult volunteers.
- Trial name
- NCT00321061
- Testing
- VRC-HIVDNA016-00, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ovarian Cancer, Primary Peritoneal Cancer
Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
The primary purpose of this study is to determine the maximally tolerated dose and spectrum of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally replicative adenovirus (Ad5-Delta 24RGD) in…
- Trial name
- Ad5Delta24RGD (NCT00562003)
- Testing
- Tenckhoff Catheter placement, Ad5-delta24RGD
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Alabama at Birmingham
Hepatocellular Carcinoma
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
- Trial name
- NCT01869088
- Testing
- Recombinant Human Adenovirus Type 5 Injection, Transartery Chemoembolization
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
EBV, CMV
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
In this study, investigators are trying to see if infusion of T cells (called CTLs) will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection.
- Conditions
- EBV, CMV, Adenovirus
- Trial name
- NCT01945814
- Testing
- CTL for CMV seropositive donors, CTL for CMV naïve donors
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Catherine Bollard